The dual-pathway peptide that out-performs single GLP-1s in the big trials. Research-grade, GMP-grade sourced, UK cold-chain — and priced per single vial from 5 to 60 mg so you can run your own titration curve.
Tirzepatide is a dual GIP + GLP-1 receptor agonist — the molecule behind Mounjaro/Zepbound. Two gut-hormone pathways instead of one, which is why it shows some of the largest weight-loss numbers of any agent in this space.
Plain: double-lock satiety — two gut hormones, so fuller for longer and a better insulin response than a single pathway. Technical: GIPR/GLP-1R dual agonism, where GIP co-stimulation potentiates the GLP-1 effects on satiety and energy expenditure, plus gastric-emptying delay and insulinotropic action.
T2D and obesity research (both approved), MASH (SURMOUNT-MASH), and cardiovascular outcomes (SURPASS-CVOT). Our 5–60 mg vials suit both entry titration and high-dose, long-course users.
Evidence: Evidence grade A. SURMOUNT-1: −20.9% to −22.5% body weight at 72 weeks, dose-dependent — the class-leading figures in the sources.
Typical research dosing: Typical titration: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly (trials up to 15 mg). Our higher-strength vials (TR50/TR60) suit high-dose users. (Typical research ranges.)
Side effects to know: Nausea, constipation, injection-site reactions — a spectrum similar to semaglutide; rare pancreatitis signal.
Research-use product, supplied from GMP-grade sources. Not a licensed medicine and not for direct human consumption. Dosing shown = typical research/clinical ranges, not a prescription.
Pay by bank transfer and your whole order is 10% off. We give you a unique order number to quote as the reference, so we match your payment and dispatch without chasing you.
Daniel Brown · Sort code 23-69-72 · Account 34389126 · GBP (GB)
Use the Card button on any vial above — a secure Stripe link, choose how many vials at the gate, done in under a minute.
Every batch ships cold-chain with its Certificate of Analysis. Tracked, insured, UK-wide, next working day dispatch.
Many start on semaglutide (single pathway, more evidence) and step up to tirzepatide if they plateau. If you want the strongest dual-pathway option from the start, tirzepatide is the premium pick.
It targets two gut-hormone receptors (GIP and GLP-1) rather than one, which in trials translates to greater appetite suppression and weight loss.
Yes — 2–8°C unreconstituted. We ship cold-chain with a storage kit; follow the COA once opened.
No — per-vial pricing, order one vial or a full course.